Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $40

Morgan Stanley analyst Matthew Harrison maintains Akero Therapeutics (NASDAQ:AKRO) with a Equal-Weight and raises the price target from $30 to $40.

byBenzinga Newsdesk

November 7, 2022

1 minute read

Morgan Stanley analyst Matthew Harrison maintains Akero Therapeutics (NASDAQ:AKRO) with a Equal-Weight and raises the price target from $30 to $40.

WesBanco, Inc. Announces Approval of a New Stock Repurchase Program To Purchase Up To An Additional 3.2M Shares Of Common Stock

By Michael Horton

Today, 5:27 AM

WesBanco, Inc. ("WesBanco") (NASDAQ:WSBC), a diversified, multi-state bank holding company, announced that the Board of Directors has authorized the adoption of a new stock repurchase plan for the purchase of

WSBC

John Wiley And Israeli Consortium MALMAD Sign Open Access Agreement; Terms Not Disclosed

By Benzinga Newsdesk

Today, 5:27 AM

https://newsroom.wiley.com/press-releases/press-release-details/2021/Wiley-MALMAD-Open-Access-Agreement/default.aspx

JW/A

5 Stocks Insiders Are Selling

By Lisa Levin

Today, 5:27 AM

When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.

ABT